Co-regulation of antigen-specific T lymphocyte responses by type I and type II cyclic AMP-dependent protein kinases (cAK)

Christine M. Braun, Shau Ku Huang, Anne Kagey-Sobotka, Lawrence M. Lichtenstein, David M. Essayan

Research output: Contribution to journalArticle

10 Citations (Scopus)

Abstract

While a differential sensitivity to cyclic AMP (cAMP)-mediated signaling between Th1 and Th2 cells has been hypothesized, differential activity of downstream signaling through cAMP-dependent protein kinase (cAK) isoforms remains unexplored. We herein report the effects of type 1- and type 2-specific cAK agonists and antagonists on proliferative responses and cytokine generation from ragweed-driven peripheral blood mononuclear cells (PBMCs) and Amb a 1-specific Th1 and Th2 clones. Rp-8-Cl- and Rp-8-CPT-cAMP were utilized as single agent antagonists of cAKI and cAKII, respectively; 8-AHA-cAMP, with and without 8-PIP-cAMP, and 8-CPT-cAMP, with and without 6-Bnz-cAMP, were used as synergistic agonist pairs specific for the cAKI and cAKII, respectively. Activation of either cAKI or cAKII individually was ineffective in down-regulating proliferative responses of PBMCs or T cell clones; concentration-response curves for the Th1 and Th2 clones were identical. Moreover, inhibition of either cAKI or cAKII individually was ineffective in overcoming the down-regulatory effects of phosphodiesterase inhibition. Activation of either cAKI or cAKII individually was ineffective in down-regulating proinflammatory cytokine generation from T cell clones (interleukin-4 from Th2; interferon-γ from Th1). However, concurrent activation of both cAKI and cAKII produced down-regulatory effects equivalent to those of the phosphodiesterase inhibitor on both proliferation and cytokine generation. These data suggest a critical role for concurrent activation of cAKI and cAKII in the functional efficacy of antigen-driven downstream signaling due to elevations of intracellular cAMP and argue against differential regulation of Th1 and Th2 responses by cAK subtypes. Copyright (C) 1998 Elsevier Science Inc.

Original languageEnglish
Pages (from-to)871-879
Number of pages9
JournalBiochemical Pharmacology
Volume56
Issue number7
DOIs
Publication statusPublished - Oct 1 1998
Externally publishedYes

Fingerprint

Cyclic AMP-Dependent Protein Kinase Type II
Cyclic AMP-Dependent Protein Kinase Type I
T-cells
Cyclic AMP
T-Lymphocytes
Antigens
Clone Cells
Cyclic AMP-Dependent Protein Kinases
Chemical activation
Cytokines
Blood Cells
Blood
Ambrosia
Th2 Cells
Th1 Cells
Phosphodiesterase Inhibitors
Phosphoric Diester Hydrolases
Interleukin-4
Interferons
Protein Isoforms

Keywords

  • cAMP-dependent protein kinase
  • Human
  • Interferon-γ
  • Interleukin-4
  • Phosphodiesterase
  • T lymphocytes

ASJC Scopus subject areas

  • Pharmacology

Cite this

Co-regulation of antigen-specific T lymphocyte responses by type I and type II cyclic AMP-dependent protein kinases (cAK). / Braun, Christine M.; Huang, Shau Ku; Kagey-Sobotka, Anne; Lichtenstein, Lawrence M.; Essayan, David M.

In: Biochemical Pharmacology, Vol. 56, No. 7, 01.10.1998, p. 871-879.

Research output: Contribution to journalArticle

Braun, Christine M. ; Huang, Shau Ku ; Kagey-Sobotka, Anne ; Lichtenstein, Lawrence M. ; Essayan, David M. / Co-regulation of antigen-specific T lymphocyte responses by type I and type II cyclic AMP-dependent protein kinases (cAK). In: Biochemical Pharmacology. 1998 ; Vol. 56, No. 7. pp. 871-879.
@article{e1c68bee190c4fd791f40d23b62c5fac,
title = "Co-regulation of antigen-specific T lymphocyte responses by type I and type II cyclic AMP-dependent protein kinases (cAK)",
abstract = "While a differential sensitivity to cyclic AMP (cAMP)-mediated signaling between Th1 and Th2 cells has been hypothesized, differential activity of downstream signaling through cAMP-dependent protein kinase (cAK) isoforms remains unexplored. We herein report the effects of type 1- and type 2-specific cAK agonists and antagonists on proliferative responses and cytokine generation from ragweed-driven peripheral blood mononuclear cells (PBMCs) and Amb a 1-specific Th1 and Th2 clones. Rp-8-Cl- and Rp-8-CPT-cAMP were utilized as single agent antagonists of cAKI and cAKII, respectively; 8-AHA-cAMP, with and without 8-PIP-cAMP, and 8-CPT-cAMP, with and without 6-Bnz-cAMP, were used as synergistic agonist pairs specific for the cAKI and cAKII, respectively. Activation of either cAKI or cAKII individually was ineffective in down-regulating proliferative responses of PBMCs or T cell clones; concentration-response curves for the Th1 and Th2 clones were identical. Moreover, inhibition of either cAKI or cAKII individually was ineffective in overcoming the down-regulatory effects of phosphodiesterase inhibition. Activation of either cAKI or cAKII individually was ineffective in down-regulating proinflammatory cytokine generation from T cell clones (interleukin-4 from Th2; interferon-γ from Th1). However, concurrent activation of both cAKI and cAKII produced down-regulatory effects equivalent to those of the phosphodiesterase inhibitor on both proliferation and cytokine generation. These data suggest a critical role for concurrent activation of cAKI and cAKII in the functional efficacy of antigen-driven downstream signaling due to elevations of intracellular cAMP and argue against differential regulation of Th1 and Th2 responses by cAK subtypes. Copyright (C) 1998 Elsevier Science Inc.",
keywords = "cAMP-dependent protein kinase, Human, Interferon-γ, Interleukin-4, Phosphodiesterase, T lymphocytes",
author = "Braun, {Christine M.} and Huang, {Shau Ku} and Anne Kagey-Sobotka and Lichtenstein, {Lawrence M.} and Essayan, {David M.}",
year = "1998",
month = "10",
day = "1",
doi = "10.1016/S0006-2952(98)00238-X",
language = "English",
volume = "56",
pages = "871--879",
journal = "Biochemical Pharmacology",
issn = "0006-2952",
publisher = "Elsevier Inc.",
number = "7",

}

TY - JOUR

T1 - Co-regulation of antigen-specific T lymphocyte responses by type I and type II cyclic AMP-dependent protein kinases (cAK)

AU - Braun, Christine M.

AU - Huang, Shau Ku

AU - Kagey-Sobotka, Anne

AU - Lichtenstein, Lawrence M.

AU - Essayan, David M.

PY - 1998/10/1

Y1 - 1998/10/1

N2 - While a differential sensitivity to cyclic AMP (cAMP)-mediated signaling between Th1 and Th2 cells has been hypothesized, differential activity of downstream signaling through cAMP-dependent protein kinase (cAK) isoforms remains unexplored. We herein report the effects of type 1- and type 2-specific cAK agonists and antagonists on proliferative responses and cytokine generation from ragweed-driven peripheral blood mononuclear cells (PBMCs) and Amb a 1-specific Th1 and Th2 clones. Rp-8-Cl- and Rp-8-CPT-cAMP were utilized as single agent antagonists of cAKI and cAKII, respectively; 8-AHA-cAMP, with and without 8-PIP-cAMP, and 8-CPT-cAMP, with and without 6-Bnz-cAMP, were used as synergistic agonist pairs specific for the cAKI and cAKII, respectively. Activation of either cAKI or cAKII individually was ineffective in down-regulating proliferative responses of PBMCs or T cell clones; concentration-response curves for the Th1 and Th2 clones were identical. Moreover, inhibition of either cAKI or cAKII individually was ineffective in overcoming the down-regulatory effects of phosphodiesterase inhibition. Activation of either cAKI or cAKII individually was ineffective in down-regulating proinflammatory cytokine generation from T cell clones (interleukin-4 from Th2; interferon-γ from Th1). However, concurrent activation of both cAKI and cAKII produced down-regulatory effects equivalent to those of the phosphodiesterase inhibitor on both proliferation and cytokine generation. These data suggest a critical role for concurrent activation of cAKI and cAKII in the functional efficacy of antigen-driven downstream signaling due to elevations of intracellular cAMP and argue against differential regulation of Th1 and Th2 responses by cAK subtypes. Copyright (C) 1998 Elsevier Science Inc.

AB - While a differential sensitivity to cyclic AMP (cAMP)-mediated signaling between Th1 and Th2 cells has been hypothesized, differential activity of downstream signaling through cAMP-dependent protein kinase (cAK) isoforms remains unexplored. We herein report the effects of type 1- and type 2-specific cAK agonists and antagonists on proliferative responses and cytokine generation from ragweed-driven peripheral blood mononuclear cells (PBMCs) and Amb a 1-specific Th1 and Th2 clones. Rp-8-Cl- and Rp-8-CPT-cAMP were utilized as single agent antagonists of cAKI and cAKII, respectively; 8-AHA-cAMP, with and without 8-PIP-cAMP, and 8-CPT-cAMP, with and without 6-Bnz-cAMP, were used as synergistic agonist pairs specific for the cAKI and cAKII, respectively. Activation of either cAKI or cAKII individually was ineffective in down-regulating proliferative responses of PBMCs or T cell clones; concentration-response curves for the Th1 and Th2 clones were identical. Moreover, inhibition of either cAKI or cAKII individually was ineffective in overcoming the down-regulatory effects of phosphodiesterase inhibition. Activation of either cAKI or cAKII individually was ineffective in down-regulating proinflammatory cytokine generation from T cell clones (interleukin-4 from Th2; interferon-γ from Th1). However, concurrent activation of both cAKI and cAKII produced down-regulatory effects equivalent to those of the phosphodiesterase inhibitor on both proliferation and cytokine generation. These data suggest a critical role for concurrent activation of cAKI and cAKII in the functional efficacy of antigen-driven downstream signaling due to elevations of intracellular cAMP and argue against differential regulation of Th1 and Th2 responses by cAK subtypes. Copyright (C) 1998 Elsevier Science Inc.

KW - cAMP-dependent protein kinase

KW - Human

KW - Interferon-γ

KW - Interleukin-4

KW - Phosphodiesterase

KW - T lymphocytes

UR - http://www.scopus.com/inward/record.url?scp=0032189190&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0032189190&partnerID=8YFLogxK

U2 - 10.1016/S0006-2952(98)00238-X

DO - 10.1016/S0006-2952(98)00238-X

M3 - Article

C2 - 9774149

AN - SCOPUS:0032189190

VL - 56

SP - 871

EP - 879

JO - Biochemical Pharmacology

JF - Biochemical Pharmacology

SN - 0006-2952

IS - 7

ER -